(Q38180719)

30 August 2017

title

Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management (English)

1 reference

30 August 2017

1 reference

1 reference

Wen Kang

1

1 reference

30 August 2017

Hsin-I Tong

series ordinal

2

1 reference

30 August 2017

Yongtao Sun

series ordinal

3

1 reference

30 August 2017

Yuanan Lu

series ordinal

4

1 reference

30 August 2017

language of work or name

1 reference

22 January 2014

1 reference

Expert Review of Gastroenterology & Hepatology

30 August 2017

published in

1 reference

30 August 2017

volume

8

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

247-266

1 reference

Evolving epidemiology of hepatitis C virus

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Electronic matching of HIV/AIDS and hepatitis C surveillance registries in three states

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Clinical and virological characteristics of hepatitis B or C virus co-infection with HIV in Indonesian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Survey of both hepatitis B virus (HBsAg) and hepatitis C virus (HCV-Ab) coinfection among HIV positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Seroprevalence of hepatitis C, hepatitis B virus and syphilis in HIV-1 infected patients in Shandong, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Clinical variables identify seronegative HCV co-infection in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Viral hepatitis and HIV infection among injection drug users in a central Iranian City

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Coinfection with HIV and hepatitis C virus among injection drug users in southern China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Seroprevalence of hepatitis virus infection in men who have sex with men aged 18-40 years in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Viral hepatitis among young men who have sex with men: prevalence of infection, risk behaviors, and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Prevalence and risk factors of hepatitis C in HIV-negative homosexual men in Sydney, Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

The incidence of syphilis, HIV and HCV and associated factors in a cohort of men who have sex with men in Nanjing, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Association of hepatitis C virus infection with sexual exposure in southern India

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Transmission of HCV in HIV-positive populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany--a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the "real-life setting" proves the concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Gaining greater insight into HCV emergence in HIV-infected men who have sex with men: the HEPAIG Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

A clustering phenomenon among HCV-1a strains among patients coinfected with HIV from Buenos Aires, Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Acute hepatitis C: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a Southern Brazilian HIV type 1 population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Lack of TGF-β production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Diminished frequency of hepatitis C virus specific interferon secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Impaired hepatitis C virus (HCV)-specific interferon-γ responses in individuals with HIV who acquire HCV infection: correlation with CD4(+) T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Impact of HIV on host-virus interactions during early hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Coinfection with HIV-1 and HCV--a one-two punch

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Haemodynamic derangement in human immunodeficiency virus-infected patients with hepatitis C virus-related cirrhosis: the role of bacterial translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Complementary role of HCV and HIV in T-cell activation and exhaustion in HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Hepatitis C coinfection enhances sensitization of CD4(+) T-cells towards Fas-induced apoptosis in viraemic and HAART-controlled HIV-1-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

HIV infection increases HCV-induced hepatocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: Implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

X4 Human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Hepatitis C and progression of HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Dynamic analysis of Th1/Th2 cytokine concentration during antiretroviral therapy of HIV-1/HCV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Short-course antiretroviral therapy in primary HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Viral hepatitis and HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

New horizons in hepatitis C antiviral therapy with direct-acting antivirals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Liver transplantation trends in the HIV population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Spontaneous clearance of HCV in HIV-hepatitis C virus coinfected liver transplant patients: prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Long-term outcomes of orthotopic liver transplantation in human immunodeficiency virus-infected patients and comparison with human immunodeficiency virus-negative cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the National Institutes of Hea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

Outcome of HCV/HIV-Coinfected Liver Transplant Recipients: A Prospective and Multicenter Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.876357

10.1586/17474124.2014.876357

21 January 2018

Identifiers

DOI

1 reference

release_oq4mcofhj5akvgz3hkwupecyfe

30 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oq4mcofhj5akvgz3hkwupecyfe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference